AI Stock Memo: CLLS - Cellectis - RankAlpha

CLLS

Rating neutralAI Memo

Cellectis

As of 2026-07-13/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-13 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

BALLI-01 pivotal Phase 2 first interim analysis remains the main de-risking event in Q4 2026 • 2026-10-31

Expected move: +29%

Biggest risk

The bear case is that Cellectis is still fundamentally a binary clinical-event story: the lead lasme-cel program remains pre-approval, eti-cel is earlier, external analyst-revision evidence is unavailable in the packet, and low coverage plus thin operating disclosure keep forward visibility weak.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The bull case is that June RMAT designation and the final Phase 1 BALLI-01 dataset improved the regulatory and clinical setup ahead of the pivotal Phase 2 interim analysis, while the May 11 company update also pointed to cash runway into Q4 2027, reducing immediate financing pressure. [#IR-2026-06-09] [#IR-2026-06-11] [#IR-2026-05-11]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-13

Base target

p=46%

Bull target

p=22%

Bear target

p=32%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

June RMAT designation and final Phase 1 BALLI-01 data improved the near-term setup
NATHALI-01 full Phase 1 dataset could broaden platform value but remains secondary
The bull case is that June RMAT designation and the final Phase 1 BALLI-01 dataset improved the regulatory and clinical setup ahead of the pivotal Phase 2 interim analysis, while the May 11 company update also pointed to cash runway into Q4 2027, reducing immediate financing pressure.

BearKey bullets

BALLI-01 remains the dominant binary risk, and a disappointing pivotal Phase 2 interim analysis in Q4 2026 would likely outweigh the June RMAT-related optimism.
Cellectis reported $188 million of cash, cash equivalents, and fixed-term deposits as of March 31, 2026 with runway into Q4 2027, but any clinical delay or weaker-than-expected data could revive financing overhang sooner than investors expect.
[#IR-2026-05-11]

WatchKey bullets

BALLI-01 pivotal Phase 2 first interim analysis remains the main de-risking event in Q4 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=46%)

Bull/Bear spread: +98% / -32%

Vs latest close: Bull +98% · Base +29% · Bear -32%

Scenario probabilities

Bull Target: $5 (p=22%)Base Target: $3 (p=46%)Bear Target: $2 (p=32%)

Commentary

Primary company news flow improved in June 2026 after the RMAT designation and EHA clinical update, and the packet includes a secondary market article tying a more than 24% after-hours rally on June 9 to that news. Still, analyst revision evidence is unavailable, social coverage is absent, and the deterministic evidence-quality score remains only 0.08 with uncertainty at 0.931, so this remains a cautious catalyst-monitoring setup rather than a confirmed rerating.

As of 2026-07-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

June RMAT designation and final Phase 1 BALLI-01 data improved the near-term setup
NATHALI-01 full Phase 1 dataset could broaden platform value but remains secondary

Scenarios

Bull Target (Scenario probability)

$5 / p=22% prob

Base Target (Scenario probability)

$3 / p=46% prob

Bear Target (Scenario probability)

$2 / p=32% prob

Price $3 as of 2026-07-17

Nearest Scenario: Base (∆ 29%)

Targets vs latest close: Bull +98% · Base +29% · Bear -32%

Sentiment & Exposure

News Sentiment (30d)

58.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
BALLI-01 pivotal Phase 2 first interim analysis remains the main de-risking event in Q4 2026
In its May 11, 2026 business update, Cellectis said the pivotal Phase 2 BALLI-01 first interim analysis is expected in Q4 2026, with BLA submission anticipated in 2028. For a low-coverage small-cap biotech, this is still the key thesis checkpoint because confirmation of efficacy and safety would materially improve program credibility, while a weak readout would likely reset expectations. [#IR-2026-05-11]
Prob 54.00% • Move 30.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

June RMAT designation and final Phase 1 BALLI-01 data improved the near-term setup
2026-07-31
Cellectis said on June 9 that the FDA granted RMAT designation to lasme-cel for relapsed or refractory B-ALL, and on June 11 presented final Phase 1 BALLI-01 data plus preliminary eti-cel data at EHA 2026. That strengthens regulatory dialogue and keeps attention on the lead allogeneic CAR-T program, but the evidence is still early clinical-stage rather than pivotal proof. [#IR-2026-06-09] [#IR-2026-06-11]
Prob 67% • Move 12% • Priced-in 63%

Long-term Catalysts

Months to a year

NATHALI-01 full Phase 1 dataset could broaden platform value but remains secondary
2026-12-31
Cellectis said on May 11 that the full Phase 1 NATHALI-01 dataset for eti-cel is expected in Q4 2026, after June 11 preliminary data showed early activity in relapsed or refractory B-cell NHL. Positive follow-through would help platform credibility beyond lasme-cel, but it remains earlier-stage and lower-conviction than the core BALLI-01 program. [#IR-2026-05-11] [#IR-2026-06-11]
Prob 46% • Move 18% • Priced-in 28%

Risks

BALLI-01 remains the dominant binary risk, and a disappointing pivotal Phase 2 interim analysis in Q4 2026 would likely outweigh the June RMAT-related optimism.
Cellectis reported $188 million of cash, cash equivalents, and fixed-term deposits as of March 31, 2026 with runway into Q4 2027, but any clinical delay or weaker-than-expected data could revive financing overhang sooner than investors expect. [#IR-2026-05-11]
Low external coverage, no usable SEC filing excerpts in the packet, and limited third-party revision data raise the risk of sharp sentiment swings around single-company updates.
The eti-cel/NATHALI-01 program is still early and preliminary, so platform-expansion upside is not yet sufficiently de-risked.

Peers

Symbol	Summary
NKTX	Nkarta is the closest packet peer for development-stage cell-therapy framing, but differences in targets and programs mean it is more useful for financing and catalyst-volatility context than for direct clinical read-through.
KRRO	Korro Bio is a better platform-risk and small-cap biotech funding comparator than a direct operating peer; it helps frame event sensitivity, but modality differences limit read-through.
VYGR	Voyager is best treated as a small-cap gene-therapy risk comparator rather than a direct peer, useful mainly for runway, partnering, and catalyst-driven sentiment context.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-13